Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma
详细信息 查看全文
- 作者：Bao-sheng Li ; Tao Zhou ; Zhong-tang Wang ; Hong-sheng Li ; Hong-fu Sun ; Zhi-cheng Zhang ; Hai-qun Lin ; Yu-mei Wei ; He-yi Gong ; Wei Huang ; Yan Yi ; Li-ying Wang
- 关键词：Esophageal cancer ; Selective lymph node late course accelerated hyper-fractionated radiotherapy ; Chemo-radiotherapy ; Capecitabine ; Cisplatin
- 刊名：Radiotherapy and Oncology
- 出版年：2009
- 出版时间：December 2009
- 年：2009
- 卷：93
- 期：3
- 页码：458-461
- 全文大小：133 K
文摘
Twelve patients with locally advanced esophageal squamous cell carcinoma were enrolled to evaluate the safety and efficacy of concurrent chemo-radiotherapy. Dose-limiting toxicity was mainly observed at Capecitabine 1500 mg. The maximum-tolerated dose/recommended dose of Capecitabine was 1000 mg. The Kaplan–Meier estimated overall l-year survival rate was 100 % .